ONC1-13B

CAS No. 1351185-54-0

ONC1-13B( —— )

Catalog No. M34358 CAS No. 1351185-54-0

ONC1-13B is a potent androgen receptor (AR) antagonist with an ic50 in the range of 59-80 nM that inhibits PSA production in androgen-sensitive human PCa LNCaP cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 683 In Stock
10MG 938 In Stock
25MG 1416 In Stock
50MG 1841 In Stock
100MG 2558 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ONC1-13B
  • Note
    Research use only, not for human use.
  • Brief Description
    ONC1-13B is a potent androgen receptor (AR) antagonist with an ic50 in the range of 59-80 nM that inhibits PSA production in androgen-sensitive human PCa LNCaP cells.
  • Description
    ONC1-13B is a potent androgen receptor (AR) antagonist with an ic50 in the range of 59-80 nM that inhibits PSA production in androgen-sensitive human PCa LNCaP cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Androgen Receptor (AR)
  • Recptor
    Androgen Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1351185-54-0
  • Formula Weight
    492.45
  • Molecular Formula
    C22H16F4N4O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1[C@@]2(N(C(=S)N1C3=CC(C(F)(F)F)=C(C#N)C=C3)C4=CC(F)=C(C(NC)=O)C=C4)CCOC2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Atraric acid

    Atraric acid derivatives as a new chemical lead structure for novel therapeutic compounds as AR antagonists.

  • Dehydroepiandrostero...

    DHEA (Dehydroisoandrosterone) is an important endogenous steroid hormone.

  • N-desmethyl Enzaluta...

    Amajor metabolite of Enzalutamide (MDV3100) which is an androgen-receptor (AR) antagonist for treatment of prostate cancer.